Researchers in Professor Justin Sonnenburg's laboratory have developed genetic tools for manipulating Bacteroides, a prominent genus of gut bacteria, for imaging, diagnostics, and therapeutic drug delivery.
Druggability of a protein is its potential to be modulated by drug-like molecules. It is important in the target selection phase. We developed DrugFEATURE to quantify druggability by assessing the microenvironments in potential small-molecule binding sites.
Stanford inventors have found that Stanniocalcin 2 (STC2) treatment following stoke leads to improved functional recovery and a pharmaceutical composition containing STC2 as an active ingredient can be used to facilitate post stroke recovery.
Stanford inventors in the Katrin Svensson laboratory have identified the protein Isthmin-1 (ISM1) as a treatment for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
Researchers at Stanford and the University of Helsinki discovered that a human secretoglobin protein found in sweat gland cells acts as a novel host defense mechanism against Lyme disease.
Despite their cytotoxic capacity, neutrophils are often co-opted by cancers to promote immunosuppression, tumor growth, and metastasis. Consequently, these cells have received little attention as potential cancer immunotherapeutic agents.
Stanford researchers have discovered that Neat1, a long non-coding RNA, regulates degradation of the MYC protein, revealing a new target for treating MYC-dependent cancers.
Stanford scientists have developed a new DNA-based technology that allows therapeutic genes to be maintained in human cells for extended periods without altering the cell's chromosomes.
Researchers in Dr. Leonore Herzenberg's lab at Stanford have developed this technology and another (see Stanford Docket S15-009) to improve the ease and accuracy of flow cytometry experiments.
Researchers in Dr. Mark Davis' lab have developed a patented method to perform multi-parametric phenotypic analysis and T cell receptor (TCR) sequencing from single sorted T cells.
Stanford researchers have developed chemically modified AAV vectors through an unnatural amino acid substitution on the capsid surface for post-production vector engineering through biorthogonal copper-free click chemistry.
Researchers at Stanford have developed fully genetically-encodable lysosome-targeting chimeras which allow for the targeted delivery of various proteins into receiver cells.